Novella Clinical and the Cardiovascular Research Foundation to collaborate on clinical trial expertise

105

Novella Clinical and the Cardiovascular Research Foundation (CRF) have announced a preferred provider collaboration that will offer a set of clinical trial services to developers of cardiovascular drugs and devices. Novella and the CRF Clinical Trials Center (CTC) will work together to provide sponsors with comprehensive clinical research services, from preclinical to post-market studies.

Novella and CRF will offer sponsors study design and execution, with access to some of the world’s leading interventional cardiologists, CRFiCOR, the Clinical Trials Center’s cardiovascular imaging laboratories and Novella’s clinical trial operations experience and medical device expertise. The two organisations will collaborate on protocol development, trial design, statistical analysis, Clinical Events Committee (CEC)/Data Safety Monitoring Board (DSMB) services, clinical monitoring, data management, product safety, project management and quality assurance. Novella and CRF are also currently involved in a number of joint global cardiovascular device studies.

“By bringing together the strengths of both a CRO and an ARO, we will be able to offer superior clinical research services, combining operational excellence with scientific and academic leadership of the highest calibre,” said Ori Ben-Yehuda, executive director of the CRF Clinical Trials Center. “We expect, over time, to further develop this collaboration with the introduction of a delivery model where sponsors are viewing trial progress in one portal, under one project manager, providing seamless delivery across joint services.”

Novella president Richard Staub said: “As experts in cardiovascular clinical trial design and execution, Novella and CRF are seizing this opportunity to leverage our combined expertise and provide sponsors with direct access to today’s leading physicians and dedicated clinical research teams to advance the next generation of cardiovascular therapies.”

(Visited 8 times, 1 visits today)